Boehringer Ingelheim (Canada) Ltd collaborated with IBM Canada in order to explore the blockchain technology usage into clinical trials. On February 12, 2019, they have announced about their collaboration at the Healthcare Information and Management Systems Society (HIMSS) conference in Orlando, Florida.
The main purpose of this collaboration is not only to explore the blockchain but also to test with the aim to provide a decentralized framework which ensures data integrity, provenance, transparency, patient empowerment, and automation processes in order to improve trial quality and patients safety at minimum cost.
Boehringer Ingelheim (Canada) Ltd is a research-driven pharmaceutical company whose aim is to improve the health of patients’ life. It is one of the top 20 pharmaceutical companies with those 50,000 employees who are working for its three business sectors like human pharmaceuticals, animal health, and biopharmaceuticals.
IBM is known for its business strategies and computing tools which are provided to academic researchers, small and large business, start-ups and developers. Whereas IBM Canada is known as a private R&D investor located in Markham, Ontario. IBM Blockchain technology provides trust and transparency. Whereas IBM Canada provides patient consent, secure health data exchange, and patient engagement in collaboration with Boehringer Ingelheim, The official website of Boehringer Ingelheim reported.
The Vice President of Medical and Regulatory Affairs at Boehringer Ingelheim (Canada) Ltd., Dr. Uli Brödl, “Our guiding philosophy is to bring value to patients and the healthcare system through innovation,” said Dr. Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. “The clinical trial ecosystem is highly complex as it involves different stakeholders, resulting in limited trust, transparency and process inefficiencies without true patient empowerment. Patients are at the heart of everything we do, so we are looking into novel solutions to improve patient safety and empowerment.”
HSBlox has declared the launch of its blockchain-based Digital Sample Manager (DSM) solution on January 29, 2019. The main purpose of this solution is created to improve visibility, transparency, and tracking of the custody chain in clinical trials. It basically provides all custody chain entities with complete sample tracking and real-time status updates. It also provides immutable records which can be used for compliance and audits, PRNewswire reported.
The chief of strategy & operations for HSBlox Lynn Carroll said, “During clinical trials, multiple biological samples are collected at various clinical sites over an extended period of time. Flawless administration of the chain of custody is critical to sample management because correct handling impacts both the course and results of clinical trials.”
Hsblox is a Blockchain healthcare technology provider who combines machine learning and blockchain (distributed ledger technology) with the main aim to address the demands for secure, real-time information sharing and interventions of the healthcare industry. It basically provides the healthcare ecosystem with patient-centric solutions through which it can develop alignment with the needs and preferences of patients. It automates multi-party transactions and generates better outcomes for each stakeholder with smart contracts deployment.
This article is for informational purposes only. The information is provided by Blockchain Technology: Its Exploration And Contribution Into Clinical Trials and while we endeavor to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the post for any purpose. It is not an offer or solicitation of an offer to buy or sell, or a recommendation, endorsement, or sponsorship of any products, services, or companies. The Blockchain Cafe does not provide investment, tax, legal, or accounting advice. Neither the company nor the author is responsible, directly or indirectly, for any damage or loss caused or alleged to be caused by or in connection with the use of or reliance on any content, goods or services mentioned in this article.